Engineer for developments of tumor-on-chip technology (M/F)

Date de clôture
Lieu(x) de travail
Paris
Secteur
Centre de Recherche
CDD
Institut Curie Research Center
Institut Curie is a major player in the research and fight against cancer. It consists of a Hospital group and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.

Laboratory

Laboratory UMR 168 - Director: Pascal Hersen

Equipe MMBM - Director: Stéphanie Descroix

https://curie.fr/equipe/descroix

This inter-disciplinary project, funded by Fondation ARC and coordinated by Maria Carla Parrini, will be developed as collaboration between Institut Curie (team of Fatima Mechta-Grigoriou), Institut Pierre-Gilles de Gennes for microfluidics (team of Stéphanie Descroix), Bichat hospital (team of Gérard Zalcman), and CNRS of Lille (team of Fabrice Soncin).

Research project

  • Title:   Generation of a vascularized lung-cancer-on-chip

Tumor-on-chip (ToC) approaches reconstitute highly-controlled tumor microenvironments in microfluidic devices. They have been recognized as breakthrough 3D models for immune-oncology research. We recently succeeded in reconstituting ex-vivo the immunotherapy response of a lung cancer ecosystem to an immune checkpoint inhibitor (anti-PD-1). Moreover, we microfabricated a functional vessel-on-chip using primary lung endothelial cells.

The project aims at generating personalized lung-cancer-on-chip platforms with clinically-relevant cell models, i.e. primary autologous cells isolated from fresh lung tumor samples. The unique controllability of ToC experimental approach will be exploited to investigate some of the immunotherapy resistance mechanisms, not linked to the molecular features of cancer cells. In particular, we will focus on the role of stromal components, cancer-associated fibroblasts and vascular endothelium, as well as of O2 concentration (hypoxia).

Our recent relevant publications

  •  Apoptosis mapping in space and time of 3D tumor ecosystems reveals transmissibility of cytotoxic cancer death.
  • Veith et al, PLoS Comput Biol. 2021 Mar 30;17(3):e1008870. doi: 10.1371/journal.pcbi.1008870.
  •  In vitro bone metastasis dwelling in a 3D bioengineered niche.
  • Han et al, Biomaterials. 2020 Dec 24;269:120624. doi: 10.1016/j.biomaterials.2020.120624.
  • Models for Immuno-oncology research. Tumour-on-chip breakthrough.
  • Parrini, Cancer Cell. 2020 Aug 10;38(2):145-147. doi: 10.1016/j.ccell.2020.07.010.
  • Fibroblast heterogeneity drives metastatic spread through distinct mechanisms in breast cancers.
  • Pelon et al, Nat Commun. 2020 Jan 21;11(1):404. doi: 10.1038/s41467-019-14134-w.
  • Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments.
  • Nguyen et al, Cell Rep. 2018 Dec 26;25(13):3884-3893.e3. doi: 10.1016/j.celrep.2018.12.015.

Candidate profile

  • Training and skills required

We are seeking for a candidate with a Master or Engineer or PhD degree, with experience in Microfluidics & Microfabrication (organ-on-chip) and/or Vascular Biology and/or Cell Biology.

  • Abilities

Autonomy, organizational capacity, team spirit, adaptability to multidisciplinarity, fluency in English.

All our opportunities are open to people with disabilities.

Contract information

  • Type of contract: fixed-term contract, Engineer position according to degree
  • Starting date:  position available immediately
  • Duration: 18 months + 18 months
  • Working time: full time
  • Remuneration: according to the current grids
  • Benefits: collective catering, reimbursement of transportation fees up to 70%, supplementary health insurance
  • Location of the position: Paris

Contact

Please send your CV, letter of motivation and 2 references, to maria-carla.parrini@curie.fr

Publication date : 25/04/2022

Deadline for application : 30/05/2022

Institut Curie is an inclusive, equal opportunity employer

and is dedicated to the highest standards of research integrity

Exemple : +33112365489
Seuls les PDF sont acceptés.